AKR1C13 inhibitors encompass a diverse group of chemicals, primarily including nonsteroidal anti-inflammatory compounds and synthetic progestins. These inhibitors function by binding to the active site of AKR1C13, an enzyme pivotal in the dehydrogenation of 17-beta-hydroxysteroids and the metabolism of various cyclic and alicyclic alcohols. The inhibition mechanisms vary slightly among different inhibitors. Chemicals like Flufenamic Acid, Indomethacin, Mefenamic Acid, Flurbiprofen, Ibuprofen, Naproxen, and Sulindac exhibit their inhibitory action primarily by direct interaction with the enzyme's active site. This interaction prevents AKR1C13 from effectively binding to its natural substrates, thus impeding its enzymatic activity. Some compounds may also influence the enzyme's conformation, further reducing its activity.
Synthetic progestins such as Medroxyprogesterone 17-Acetate, Norethindrone, and Progesterone, on the other hand, inhibit AKR1C13 by a competitive mechanism, wherein these molecules mimic the natural substrates of the enzyme and compete for binding at the active site. This competition effectively reduces the enzyme's ability to process its natural substrates, thereby modulating its role in steroid metabolism. Trilostane, another notable inhibitor, distinguishes itself by irreversibly binding to the active site of AKR1C13, leading to a long-lasting reduction in enzymatic activity. Epalrestat, while not an NSAID or progestin, exerts its inhibitory effect by interacting with the cofactor binding site of AKR1C13, particularly affecting the enzyme's ability to utilize NAD and NADP for the reduction of substrates. The inhibition of AKR1C13 by these chemicals is significant as it directly impacts the enzyme's role in steroid metabolism and alcohol processing. By targeting the active site and altering enzyme conformation or competing with natural substrates, these inhibitors can effectively modulate the biological functions mediated by AKR1C13. Understanding the specific inhibition mechanisms of these compounds contributes to a deeper comprehension of the regulation of steroid hormone biosynthesis and the metabolism of various alcohols, which are crucial in physiological processes and disease states.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Flufenamic acid | 530-78-9 | sc-205699 sc-205699A sc-205699B sc-205699C | 10 g 50 g 100 g 250 g | $27.00 $79.00 $154.00 $309.00 | 1 | |
Flufenamic Acid, a nonsteroidal anti-inflammatory drug, inhibits AKR1C13 by binding to its active site, thereby preventing the reduction of substrates. | ||||||
Indomethacin | 53-86-1 | sc-200503 sc-200503A | 1 g 5 g | $29.00 $38.00 | 18 | |
Indomethacin acts as an inhibitor by interacting with the enzyme's active site, hindering its ability to process substrates like 17-beta-hydroxysteroids. | ||||||
Norethindrone | 68-22-4 | sc-204822 sc-204822B sc-204822A sc-204822C | 250 mg 500 mg 1 g 5 g | $39.00 $70.00 $128.00 $507.00 | ||
As a synthetic progestin, Norethindrone competes with endogenous substrates for AKR1C13's active site, thus decreasing its enzymatic activity. | ||||||
Progesterone | 57-83-0 | sc-296138A sc-296138 sc-296138B | 1 g 5 g 50 g | $20.00 $52.00 $298.00 | 3 | |
Progesterone acts as an inhibitor by directly binding to AKR1C13 and altering its conformation, which in turn impedes its enzymatic activity. | ||||||
Trilostane | 13647-35-3 | sc-208469 sc-208469A | 10 mg 100 mg | $228.00 $1217.00 | 2 | |
Trilostane inhibits AKR1C13 by binding irreversibly to the active site, thereby blocking substrate access and reducing enzymatic activity. | ||||||
Mefenamic acid | 61-68-7 | sc-205380 sc-205380A | 25 g 100 g | $106.00 $208.00 | 6 | |
This nonsteroidal anti-inflammatory drug inhibits AKR1C13 by binding to the enzyme's active site, impeding its interaction with 17-beta-hydroxysteroids. | ||||||
Epalrestat | 82159-09-9 | sc-218319 | 10 mg | $200.00 | 2 | |
Epalrestat inhibits AKR1C13 by interacting with the enzyme's cofactor binding site, reducing its ability to utilize NAD/NADP for substrate reduction. | ||||||
Flurbiprofen | 5104-49-4 | sc-202158 sc-202158A | 100 mg 1 g | $70.00 $106.00 | ||
As a nonsteroidal anti-inflammatory drug, Flurbiprofen inhibits AKR1C13 by competing with natural substrates for binding at the active site. | ||||||
Ibuprofen | 15687-27-1 | sc-200534 sc-200534A | 1 g 5 g | $53.00 $88.00 | 6 | |
Ibuprofen, a widely used NSAID, inhibits AKR1C13 by interfering with its active site, thus reducing its enzymatic activity in processing 17-beta-hydroxysteroids. | ||||||
Naproxen | 22204-53-1 | sc-200506 sc-200506A | 1 g 5 g | $24.00 $41.00 | ||
Naproxen acts as an inhibitor by binding to the active site of AKR1C13, impeding its ability to reduce substrates involved in steroid metabolism. | ||||||